Hexylcaine

Summary

Hexylcaine (CHEMBL1197) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 261.36 Da · C16H23NO2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1197
Name	Hexylcaine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	10770
Molecular formula	C16H23NO2
Molecular weight	261.36
InChIKey	DKLKMKYDWHYZTD-UHFFFAOYSA-N

SMILES: CC(CNC1CCCCC1)OC(=O)C2=CC=CC=C2

IUPAC name: 1-(cyclohexylamino)propan-2-yl benzoate

Also known as: Hexilcaina, Hexylcaine, Osmocaine, hexylcaine, HEXYLCAINE

Parent form; salt/anhydrous children: CHEMBL1200715

Patent coverage: 1,140 distinct patent families (4,372 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Sodium channel alpha subunits; brain (Types I, II, III).

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
SCN1A	5.16	IC50	7000	nM	CHEMBL_ACT_352488

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).